6533b828fe1ef96bd12885c8
RESEARCH PRODUCT
Antiplatelet Antibodies Do Not Predict the Response to Intravenous Immunoglobulins during Immune Thrombocytopenia
Arthur ImbachH. GreigertChristelle MausserveyNadine Magy-bertrandLaurent VoillatBernard BonnotteGuillaume MoureySethi OuandjiSylvain AudiaEric DeconinckMaxime SamsonThibault GhesquièreDenis CaillotNicolas FalvoJean-baptiste PicqueThomas Rogiersubject
IVIgPhagocytosislcsh:Medicine030204 cardiovascular system & hematologyArticle03 medical and health sciencesantiplatelet antibodies0302 clinical medicinehemic and lymphatic diseasesmedicinePlateletReceptor030304 developmental biologyAutoimmune diseasechemistry.chemical_classification0303 health sciencesbiologybusiness.industrylcsh:RAutoantibodyGeneral Medicinemedicine.diseasechemistryMechanism of actionimmune thrombocytopeniaImmunologybiology.proteinAntibodymedicine.symptomGlycoproteinbusinesscirculatory and respiratory physiologydescription
Immune thrombocytopenia (ITP) is a rare autoimmune disease due to autoantibodies targeting platelet glycoproteins (GP). The mechanism of platelet destruction could differ depending on the specificity of antiplatelet antibodies: anti-GPIIb/IIIa antibodies lead to phagocytosis by splenic macrophages, in a Fc&gamma
year | journal | country | edition | language |
---|---|---|---|---|
2020-06-25 | Journal of Clinical Medicine |